ethyl 3-(4-bromo-1H-indazol-1-yl)propanoate | 1312008-70-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 英文名称: ethyl 3-(4-bromo-1H-indazol-1-yl)propanoate
• 英文别名: ethyl 3-(4-bromoindazol-1-yl)propanoate
• CAS: 1312008-70-0
• 化学式: C₁₂H₁₃BrN₂O₂
• 分子量: 297.151
• InChiKey: QKWSSHFWRXIOCZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  44.1
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ethyl 3-(4-bromo-1H-indazol-1-yl)propanoate 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 potassium acetate 、 potassium carbonate 、 间氯过氧苯甲酸 作用下， 以 1,4-二氧六环 、 乙醇 、 乙腈 为溶剂， 反应 6.0h， 生成 Ethyl 3-[4-[(3-cyano-4-propan-2-yloxyphenyl)methoxy]indazol-1-yl]propanoate
  参考文献：
  名称：

  EP3892616

  摘要：

  公开号：
• 作为产物：
  描述：

  3-溴-2-甲基苯胺 在 potassium acetate 、 乙酸酐 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 氯仿 、 乙腈 为溶剂， 生成 ethyl 3-(4-bromo-1H-indazol-1-yl)propanoate
  参考文献：
  名称：

  OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS

  摘要：

  氧代唑取代吲唑衍生物的化学式（I）或其药用盐具有药理活性，公开了它们的制备方法、含有它们的药物组合物以及它们在治疗由S1P1受体介导的各种疾病中的用途。

  公开号：

  US20120283297A1

文献信息

• [EN] OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS<br/>[FR] DÉRIVÉS D'INDAZOLE SUBSTITUÉS PAR OXADIAZOLE DESTINÉS À ÊTRE UTILISÉS COMME AGONISTES DU RÉCEPTEUR DE SPHINGOSINE-1-PHOSPHATE 1 (S1P1)
  申请人：GLAXO GROUP LTD

  公开号：WO2011072488A1

  公开（公告）日：2011-06-23

  Oxadiazole substituted indazole derivatives of formula (I) or pharmaceutical salts thereof having pharmacological activity, processes for their preparation, pharmaceutical compositions containing them and their uses in the treatment of various disorders mediated by S1P1 receptor are disclosed.

  氧代唑取代吲唑衍生物的化学式（I）或其药用盐具有药理活性，公开了它们的制备方法、含有它们的药物组合物以及它们在治疗由S1P1受体介导的各种疾病中的用途。
• OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS
  申请人：Bailey James

  公开号：US20120283297A1

  公开（公告）日：2012-11-08

  Oxadiazole substituted indazole derivatives of formula (I) or pharmaceutical salts thereof having pharmacological activity, processes for their preparation, pharmaceutical compositions containing them and their uses in the treatment of various disorders mediated by S1P1 receptors are disclosed.

  氧代唑取代吲唑衍生物的化学式（I）或其药用盐具有药理活性，公开了它们的制备方法、含有它们的药物组合物以及它们在治疗由S1P1受体介导的各种疾病中的用途。
• AROMATIC RING DERIVATIVE AS IMMUNOREGULATION AND PREPARATION METHOD AND APPLICATION OF AROMATIC RING DERIVATIVE
  申请人：Shanghai Jemincare Pharmaceuticals Co., Ltd.

  公开号：EP3892616A1

  公开（公告）日：2021-10-13

  Relating to a compound represented by formula (I) and a pharmaceutically acceptable salt of the compound, and an application of the compound as an S1P1 agonist.

  涉及一种由式 (I) 代表的化合物和该化合物的药学上可接受的盐，以及该化合物作为 S1P1 激动剂的应用。
• [EN] AROMATIC RING DERIVATIVE AS IMMUNOREGULATION AND PREPARATION METHOD AND APPLICATION OF AROMATIC RING DERIVATIVE<br/>[FR] DÉRIVÉ CYCLIQUE AROMATIQUE UTILISÉ EN TANT QU'AGENT D'IMMUNORÉGULATION, PROCÉDÉ DE PRÉPARATION ET UTILISATION D'UN DÉRIVÉ CYCLIQUE AROMATIQUE<br/>[ZH] 作为免疫调节的芳环衍生物及其制备方法和应用
  申请人：SHANGHAI JEMINCARE PHARMACEUTICALS CO LTD

  公开号：WO2020114475A1

  公开（公告）日：2020-06-11

  涉及一种式(Ⅰ)所示化合物及其药效上可接受的盐，以及该化合物作为S1P1激动剂的应用。
• Optimization of Sphingosine-1-phosphate-1 Receptor Agonists: Effects of Acidic, Basic, and Zwitterionic Chemotypes on Pharmacokinetic and Pharmacodynamic Profiles
  作者：John Skidmore、Jag Heer、Christopher N. Johnson、David Norton、Sally Redshaw、Jennifer Sweeting、David Hurst、Andrew Cridland、David Vesey、Ian Wall、Mahmood Ahmed、Dean Rivers、James Myatt、Gerard Giblin、Karen Philpott、Umesh Kumar、Alexander Stevens、Rino A. Bit、Andrea Haynes、Simon Taylor、Robert Watson、Jason Witherington、Emmanuel Demont、Tom D. Heightman

  DOI：10.1021/jm5010336

  日期：2014.12.26

  The efficacy of the recently approved drug fingolimod (FTY720) in multiple sclerosis patients results from the action of its phosphate metabolite on sphingosine-1-phosphate S1P(1) receptors, while a variety of side effects have been ascribed to its S1P(3) receptor activity. Although S1P and phospho-fingolimod share the same structural elements of a zwitterionic headgroup and lipophilic tail, a variety of chemotypes have been found to show S1P(1) receptor agonism. Here we describe a study of the tolerance of the S1P(1) and S1P(3) receptors toward bicyclic heterocycles of systematically varied shape and connectivity incorporating acidic, basic, or zwitterionic headgroups. We compare their physicochemical properties, their performance in in vitro and in vivo pharmacokinetic models, and their efficacy in peripheral lymphocyte lowering. The campaign resulted in the identification of several potent S1P(1) receptor agonists with good selectivity vs S1P(3) receptors, efficacy at <1 mg/kg oral doses, and developability properties suitable for progression into preclinical development.